First, the EGF receptor, a known activator of the ERK1/2 pathway, is expressed in more than 70% of colorectal cancers [53]; treatment with the EGF receptor monoclonal antibody cetuximab improves overall survival in patients with colorectal cancer [54]. This evidence concerns the gene MAPK3 and colorectal cancer.